Replies to post #14195 on Aphria Inc (fka APHA)

[john1311]

Germany is the key to Europe. Before the Brits, French, Spanish or Italians, the Germans could legalise... Merkel, the most popular world leader, was positive for legalising during the government negotiations with the greens and business parties, but that government failed to come together...
There is a cannabis pilot programmes in Berlin, that could influence the whole of Germany .... whatever the Germans do the rest of Europe follows... Prohibition Partners express that across Europe "a tidal change in policy might not be far away." If so, Aphria is in a fabulous position to ride that wave.

[john1311]

A private company survey in German in April found that "Almost 81 percent support legalization of cannabis in various forms."

[john1311]

London-based manager aims to raise Europe’s biggest cannabis fund

(This is from the Financial Times today: 22-Sept-2020.... The FT today has two stories on cannabis today, and readers comments are about 80% to 90% pro legalisation)

Europe’s small market for investing in cannabis is showing signs of life, with a London-based investment firm focused on wealthy individuals hoping to raise the region’s biggest dedicated fund.

North America dominates cannabis investment, with 12 out of 14 cannabis-focused exchange traded funds globally listed there, according to data group ETFGI. Returns have often been poor.

But Chrystal Capital Partners believes a growing wave of legislation will boost the popularity of cannabis investment, and its potential returns. It is hoping to raise an initial $100m for the Verdite Capital Fund, an actively managed fund launched on Monday, before growing it to $200m through a later fundraising.

“We think this will be a highly regulated industry in 10 years’ time,” said Kingsley Wilson, an investment partner at the firm, acknowledging that regulatory risk had deterred many private equity and institutional investors from the sector. “Regulation and funding will underpin the market transition and how it moves from an illegal to a legal market.”

Chrystal’s strategy will focus on medical marijuana, cannabis-derived drugs and so-called CBD — a cannabinoid that does not make users feel high. About half of its assets will be invested in North America and at least 35 per cent in Europe. It will avoid companies supplying marijuana for recreational use, Chrystal said.

https://www.ft.com/content/d590d2c2-5292-4ff8-9a24-cf6900989a7e